Cybin Inc. filings document Helus Pharma's status as a foreign issuer reporting current events through Form 6-K materials and related exhibits. The filings include company news releases covering the HLP003 and HLP004 clinical programs, regulatory designations, clinical research collaborations, scientific advisory matters, and management changes.
The company's regulatory record also covers capital-structure disclosure, shareholder voting matters, governance matters, clinical or regulatory disclosures, operating and financial results, and risk-oriented cautionary statements associated with its clinical-stage pharmaceutical business.
Helus Pharma Inc. announced that co-founders Eric So and Paul Glavine have stepped down from their executive and consulting roles and will continue as members of the Board of Directors. The company appointed existing director Mark Lawson as independent Chair, effective immediately, and named So Chairman Emeritus, an honorary title. So had served as President and Executive Chairman; Glavine had served as Chief Growth Officer since 2021. Michael Halstead is the company’s Chief Executive Officer.
Helus continues to anticipate reporting topline data from its Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder in Q4 2026. HLP003 is in Phase 3 clinical development for adjunctive treatment of major depressive disorder and has received FDA Breakthrough Therapy Designation; HLP004 is in Phase 2 for generalized anxiety disorder.
Helus Pharma Inc. director Freda C. Lewis-Hall reported 100,000 common shares held directly on October 13, 2026. She also reported options held by Intelmed, LLC, an entity she owns and controls, covering 25,000 common shares at a $5.99 exercise price. The options vest quarterly over two years beginning December 31, 2025, and expire October 1, 2035. Her reported direct holdings also include 25,000 restricted share units, each representing a right to one common share and vesting November 20, 2026.
Helus Pharma Inc. (HELP) lists director Amir Inamdar’s reported holdings as of October 13, 2026: 224,332 common shares held by Zephyr Life Sciences Ltd., described as a United Kingdom corporation owned and controlled by him, and 3,490 common shares held directly. The disclosed position also includes 66,668 unvested restricted share units from an October 1, 2025 grant; each unit represents a right to receive one common share.
Helus Pharma Inc. (HELP) director Grant Froese reported ownership positions as of October 13, 2026, including 19,737 directly held warrants tied to 19,737 underlying common shares. The warrants have a US$17.37 exercise price and expire August 20, 2030. The exercise price reflects conversion from C$24.32 at C$1.4 = US$1.00. Froese also reported 156,000 common shares held by Greywolf Management Services Inc., which he owns and controls, and 5,263 common shares held by his spouse.
Helus Pharma Inc. director Eric Hoskins reported holdings dated October 13, 2026: 156,000 Common Shares held by Lucky Square Holdings Inc., which the associated footnote identifies as owned and controlled by him; 1,316 Common Shares held directly; and 1,316 Common Shares held by his spouse. Lucky Square also holds warrants covering 30,263 Common Shares, with a US$6.79 exercise price converted from C$9.50 at C$1.4 = US$1.00 and an expiration date of November 15, 2030.
Helus Pharma Inc. (HELP) reports director Mark Lawson’s common-share holdings as of October 13, 2026: 3,026 shares held directly and 157,000 shares held by Four Paths Partners Ltd. The second entry identifies Four Paths Partners Ltd. as the holder and states that Lawson owns and controls the corporation. The positions are presented separately.
Helus Pharma Inc. (HELP) director Theresa Firestone reported direct ownership of 76,879 common shares on October 13, 2026. The entry records a holding.
Helus Pharma Inc. (HELP) said the HLP003 APPROACH Phase 3 topline data readout remains on track for Q4 2026, while its next HLP004 Phase 2 monotherapy study for generalized anxiety disorder is expected to initiate in Q1 2027. The company completed enrollment of 223 participants in APPROACH in July 2026; enrollment continues in EMBRACE, its second pivotal HLP003 study.
The HLP004 study will assess two 30 mg administrations. Approximately 144 adults will be randomized 1:1 to 30 mg HLP004 or inactive placebo, with change in HAM-A total score assessed at Week 6 as the primary endpoint and Week 12 as the key secondary endpoint. HLP003 has FDA Breakthrough Therapy Designation. Helus cautioned that clinical-trial timelines may not be met.
Helus Pharma Inc. announced Suresh Durgam, M.D.’s appointment to its Board of Directors, subject to Cboe Canada approval. Dr. Durgam previously served on the company’s Scientific Advisory Board and has more than two decades of CNS drug-development experience across clinical development, medical affairs, regulatory strategy and pharmacovigilance. Helus Pharma is developing HLP003 in Phase 3 for adjunctive treatment of major depressive disorder; HLP003 has FDA Breakthrough Therapy Designation. Its HLP004 program is in Phase 2 for generalized anxiety disorder.
Helus Pharma Inc. (HELP) will host an investor presentation on October 21, 2026, at 9:00 a.m. EDT. Discussion topics include HLP003, in Phase 3 development for adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder. The webcast will also include key opinion leaders’ perspectives on depression and anxiety treatments and a question-and-answer session with executive leadership. An archived webcast will be available on the company’s website following the presentation.